Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion

Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion

Source: 
CP Wire
snippet: 
  • Arrowhead will receive $175 million upfront
  • J&J will make a $75 million equity investment
  • Janssen receives a worldwide exclusive license to the ARO-HBV program